The left ventricular assist effect and biocompatibility study of a novel para-aortic counterpulsation device.
To evaluate the hemodynamic characteristics and biocompatibility of a new para-aortic counterpulsation device in animal experiment studies. Para-aortic counterpulsation device (PACD), a monoport device, consists of a blood chamber anastomosed to the descending aorta by means of a valveless graft and an air chamber connected to IABP machine. Hemodynamic parameters during the PACD-assisted beats were compared with those during the unassist beats. Acute heart failure was induced in all animals, and the hemodynamic effects of PACD were then reassessed. We successfully induced heart failure in all cases, in conditions of which cardiac output (CO) and MAP decreased 17.6% and 27.7% respectively, and PCWP increased 57.7%. Hemodynamic indexes, cerebral and heart perfusion improved significantly after PACD assisting. PACD activation increased significantly CO and MAP 6.29% and 2.04% respectively. Both of SAP and DAP decreased significantly from 85.00 to 81.88 mmHg and 59.63 to 54.63 respectively, at the same time, MADP increased 19.4%, after PACD assist. The value of MDLMF, LMF and CSF was increased by 14.0%, 13.8% and 11.6% respectively. LCAF increased by 11.23%, after PACD assist. The PFH increased significantly in the first six hours. There was no statistically significant difference in the last two hours. When the acute animal experiments were completed, there were no infarct ischemic, thrombosis change in organs by Gross and histologic observation. PACD with good biological compatibility significantly reduced the left ventricular afterload, increased diastolic arterial pressure and myocardial perfusion, improved heart function and cerebral perfusion.